Dr Daniel Billen

Guest Contributor
November 15, 2010

Dr Daniel Billen has been appointed chair of the recently created Ontario Bioscience Economic Strategy Team (OBEST) advisory committee. Billen is GM Amgen Canada and was chosen to head up an initiative to develop an evergreen strategy for sustaining the province's health sciences industry. An initiative of the Ontario Bioscience Industry Organization (OBIO) — a council of chief executive officers of Ontario-based bioscience companies financially supported by the provincial government — the 16-member OBEST committee will consult widely and focus on the convergence of industry, academia, government, patients, capital markets, and health, finance, research and innovation in government. The strategy will be constantly revisited and revised as OBEST conducts its consultations….


Other News






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.